Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
Details :
Product Name : Repagyn
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 15, 2024
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Inositol,Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Details :
Product Name : Inofolic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Inositol,Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polydextrose Iron Complex
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSyent Announces Launch of New FeraMAX Pd Maintenance 45
Details :
Product Name : FeraMAX
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Polydextrose Iron Complex
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable